Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02392988
Other study ID # 0002-15
Secondary ID
Status Not yet recruiting
Phase N/A
First received March 2, 2015
Last updated March 18, 2015
Start date May 2015
Est. completion date May 2018

Study information

Verified date February 2015
Source Meir Medical Center
Contact Liat Edry, PhD
Phone 0508520296
Email liatedry@gmail.com
Is FDA regulated No
Health authority Israel: Ethics CommissionIsrael: Ministry of Health
Study type Interventional

Clinical Trial Summary

In recent years, it is accepted to induce birth at week 41 in order to reduce the risk in surplus pregnancies. It was found that after 41 weeks, there is a significant increase in pregnancy complications including meconium liquor, shoulder dystocia and fetal death in uterus.

Induction at 41 weeks was found to reduce the risk of complications described above, without taking the risk of cesarean section and, therefore, the recommendation of the Israel Society of Maternal Fetal Medicine, is to induce birth for women who completed 41 weeks of pregnancy.

Induction is performed mechanically by entering a balloon to the cervix or by medicated prostaglandins and later, intravenous Pitocin to most women. The process takes two to three days with about 60-70% success rate.

In recent years there has been a growing awareness to use natural methods to start labor.

Many women tend to turn to natural medicine in order to reduce the need for conventional drugs to start labor.

Given the lack of research on the issue and considering the rising demand of the involvement of alternative medicine in labor induction process, the investigators decided to carry out research on this subject.


Description:

To the study will be recruited women who have completed 40 weeks of pregnancy and have not yet given birth, with proper evaluation of mother and fetus.

Women who are fit to participate and had given their consent, will be computerized randomized to one of three groups.

Research groups:

1. Group who receives acupuncture treatment in order to accelerate the development of birth.

2. Group who receives sham treatment - non acupuncture treatment, but a similar treatment, so that the patient is unable to know whether she is receiving a real acupuncture treatment, or the similar one, which has no effect on the patient.

3. Group who does not receive any treatment and will be reviewed a week later, unless a spontaneous birth will be developed. (Procedure accepted today) The study will be carried out between week 40 and week 41. During the week acupuncture treatment, sham treatment or conservative follow-up will be carried out, depending on the study group differentiation.

All women who will be randomized to the treatment groups, will fill a preliminary questionnaire for acupuncture treatment.

The course of treatment: During the week of study the women in the treatments groups will receive treatment every 48-72 hours, a maximum of three treatments.

Measures will be taken on the following week or two when the women will come to give birth.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 600
Est. completion date May 2018
Est. primary completion date May 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Women past their due date (week 40)

2. Proper dating of pregnancy

3. Uncomplicated pregnancy

4. Normal evaluation as part of the mother and fetus routine examination on week 40

5. Singleton pregnancy

6. No contraindication for vaginal birth

7. No significant signs of birth

Exclusion Criteria:

1. Past Cesarean Section

2. Women who have undergone acupuncture treatment during pregnancy

3. Women who did not undergo separation membranes

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
acupuncture treatment
acupuncture treatment
Placebo Comparator
Placebo Comparator

Locations

Country Name City State
Israel Meir Medial Center Kfar Saba

Sponsors (3)

Lead Sponsor Collaborator
Meir Medical Center Clalit Health Services, Reidman college

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of women who received birth induction after week 41 three weeks No
Secondary Number of women who had SROM (spontaneous rupture of membranes) or AROM (artificial rupture of membranes). three weeks No
Secondary Duration of labour three weeks No
Secondary Time past from treatment (acupuncture vs. placebo) till labour three weeks No
Secondary Hg before and after labour three weeks No
Secondary Number of women who received epidural three weeks No
Secondary Type of labour three weeks No
Secondary Apgar score after birth three weeks No